C O N T E M P O R A R Y S U B J E C T• This MCO's solution to the clinical, financial, and operational challenges of managing office-administered specialty pharmaceuticals involved (a) the transfer of certain office-administered, nononcology medical injectable drugs (MIDs) from "buy and bill" physician reimbursement using HCPCS (J) codes to purchase from a single, exclusive SPP at discounted reimbursement rates based on National Drug Code (NDC) numbers, and (b) reduction in physician reimbursement for MIDs to the SPP rates for medical offices that opted to continue to use the buy-and-bill method.